Dermatologic Manifestations of Rubinstein-Taybi Syndrome

Back

Background

In 1963, Rubinstein and Taybi first described Rubinstein-Taybi syndrome (RSTS) (Mendelian Inheritance in Man [MIM] #180849). Rubinstein-Taybi syndrome is a well-delineated malformation syndrome characterized by facial abnormalities, broad thumbs, broad great toes, short stature, and mental retardation.[1, 2, 3]

For additional information, see the article Rubinstein-Taybi Syndrome.

Pathophysiology

The locus of Rubinstein-Taybi syndrome is located on band 16p13.3, which includes a gene encoding a binding protein for cyclic adenosine monophosphate–response element binding protein (CBP) (CREBBP or CBP gene) that is responsible for the phenotype of Rubinstein-Taybi syndrome. CBP spans approximately 150 kb with 31 exons, and its cDNA is 9 kb in length.[4, 5, 6, 7] Genetically based growth retardation and feeding difficulties are the main problems in early life; however, respiratory tract infections and complications from congenital heart disease are primary causes of morbidity and mortality in infancy.

Milder variants of Rubinstein-Taybi syndrome have been reported, with less retardation and more subtle clinical features. These patients have been referred to as having "incomplete” Rubinstein-Taybi syndrome.

Etiology

Mutations in two genes, CBP (CREBBP) and EP300, have been identified in affected individuals.[8, 9]

CBP and EP300 are ubiquitously expressed homologous proteins that act as transcriptional co-activators. Both genes are highly conserved, and their proteins are thought to have 2 functions: (1) formation of a bridge or scaffold between the DNA-binding transcription factors and the RNA polymerase II complex and (2) serving as histone acetyltransferases that open the chromatin structure, a process essential for gene expression.[10] During organogenesis, CBP is expressed in specific cell types of the developing heart, vasculature, skin, lungs, and liver. Many of these tissues and organs are known to be affected in mutant mice lacking CBP and in patients with Rubinstein-Taybi syndrome.

Disruption of the human CBP gene, either by gross chromosomal rearrangements or by point mutations, leads to Rubinstein-Taybi syndrome. Translocations and inversions involving band 16p13.3 form the minority of CBP mutations, while microdeletions occur more frequently (approximately 10%). Point mutations and small deletions or insertions of the CBP and EP300 genes 3,18,19, as well as deletions and duplications 41000 bp in length to megabases, have been shown to lead to Rubinstein-Taybi syndrome.[10] Blough et al[11] reported that no phenotypic differences were observed among patients with partial deletion, complete deletion, and nondeletion, supporting a haploinsufficiency model for Rubinstein-Taybi syndrome.

Roelfsema et al[12] reported EP300 gene mutations in 3 (3.3%) of 92 patients with either true Rubinstein-Taybi syndrome or different syndromes resembling Rubinstein-Taybi syndrome. The EP300 gene on band 22q13 encodes a protein, p300, that is highly similar to CREBBP. At present, the cause of Rubinstein-Taybi syndrome remains unknown in approximately half the patients. Both CBP and EP300 interact with several cofactors (p/CAF, CITED1, CITED4), which can also be involved in Rubinstein-Taybi syndrome and would indicate further genetic heterogeneity.

Individuals reported with mutations in EP300 have a milder skeletal phenotype, lacking typical broadening and angulation of the thumb and hallux.

For both genes, a mutation database is available that also includes unpublished mutations, as follows:

Epidemiology

Frequency

The prevalence of Rubinstein-Taybi syndrome in the general population is approximately 1 case per 300,000 persons and is as high as 1 case per 10,000 live births. Cantani and Gagliesi[13] reported that Rubinstein-Taybi syndrome is not so rare and is present in approximately 1 in 600 patients seen in mental retardation clinics. Most cases of Rubinstein-Taybi syndrome are sporadic, although it has been reported in monozygotic twins. Families with more than 1 affected child are extremely rare.[14]

Race

Rubinstein-Taybi syndrome has no racial predilection.

Sex

Rubinstein-Taybi syndrome has no sexual predilection.

Age

The syndrome can often be recognized in the neonatal period by the typical abnormalities seen in the thumbs, the great toes, and the face.

Prognosis

The survival rate is good, with frequent reports of adult patients with Rubinstein-Taybi syndrome. Patients with Rubinstein-Taybi syndrome have an increased risk of developing malignancies, including brain tumors (meningioma, medulloblastoma) and hematologic malignancies (leukemia).[14, 15]  Genetically based growth retardation and feeding difficulties are the principal problems hindering the development of children. Respiratory tract infections and complications resulting from congenital heart disease are primary causes of morbidity and mortality in infancy. Milestones in patients with Rubinstein-Taybi syndrome are delayed.

Patient Education

The Web site Rubinstein-Taybi Syndrome is devoted to people with Rubinstein-Taybi syndrome and their families. Photographs of children and adults with Rubinstein-Taybi syndrome, Rubinstein-Taybi syndrome organizations around the world, and lists of books and other resources for families are available.

History

Patients may present with the following:

Physical Examination

Facial abnormalities are as follows (see images below list):

Digital abnormalities are as follows (see image below):

Ocular abnormalities are as follows[17] :

Abnormalities of growth and development are as follows:

Skeletal abnormalities are as follows:

Skin findings are as follows:

Cardiovascular system findings are as follows[24] :

Other conditions are as follows:

Complications

Cardiac arrhythmias can result if succinylcholine is administered. Sleeping problems include insomnia; glossoptosis can cause sleep apnea. Laryngeal wall collapsibility may cause sleeping problems and difficulty during anesthesia.

Imaging Studies

The types of imaging studies performed depend on the clinical manifestations of the patient. For example, a patient with skeletal abnormalities requires further radiologic investigations, such as CT scanning and MRI.

Other Tests

Note the following:

Procedures

Note the following:

Medical Care

The wide spectrum of clinical manifestations requires disease management tailored to the problems of each patient. Physical therapy, speech and feeding therapy, and special education are important supportive measures in infancy.

Surgical Care

Individualize surgical treatment based on findings in the patient. For example, a patient with a congenital heart defect may need cardiothoracic intervention.

Consultations

Prenatal testing for at-risk pregnancies is possible if the disease-causing CBP mutation or deletion in the family is known.

Consult a cardiologist for evaluation of congenital heart disease.

Consult a neurologist for evaluation of EEG and other neurologic abnormalities.

Consult an ophthalmologist for evaluation of eye abnormalities.

Consult an orthopedist for evaluation of skeletal abnormalities.

Consult a pediatric dentist every 6 months beginning at age 1 year.[26]

Long-Term Monitoring

Physical therapy, speech and feeding therapy, and special education are important supportive therapies in infancy.

Author

Zeljko P Mijuskovic, MD, PhD, Associate Professor of Dermatology, Department of Dermatology and Venereology, Military Medical Academy, Serbia

Disclosure: Nothing to disclose.

Coauthor(s)

Djordjije Karadaglic, MD, DSc, Professor, School of Medicine, University of Podgorica, Podgorica, Montenegro

Disclosure: Nothing to disclose.

Ljubomir Stojanov, MD, PhD, Lecturer in Metabolism and Clinical Genetics, University of Belgrade School of Medicine, Serbia

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Acknowledgements

Mark A Crowe, MD Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine

Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society

Disclosure: Nothing to disclose.

References

  1. Bedeschi MF, Crippa BL, Colombo L, Guez S, Cerruti M, Fogliani R, et al. Unusual prenatal presentation of Rubinstein-Taybi syndrome: A case report. Am J Med Genet A. 2014 Jul 29. [View Abstract]
  2. Beets L, Rodríguez-Fonseca C, Hennekam RC. Growth charts for individuals with Rubinstein-Taybi syndrome. Am J Med Genet A. 2014 Jul 2. [View Abstract]
  3. Tirali RE, Sar C, Cehreli B. Oro-facio-dental findings of rubinstein-taybi syndrome as a useful diagnostic feature. J Clin Diagn Res. 2014 Jan. 8(1):276-8. [View Abstract]
  4. Petrij F, Dauwerse HG, Blough RI, et al. Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations. J Med Genet. 2000 Mar. 37(3):168-76. [View Abstract]
  5. Hamilton MJ, Newbury-Ecob R, Holder-Espinasse M, Yau S, Lillis S, Hurst JA, et al. Rubinstein-Taybi syndrome type 2: report of nine new cases that extend the phenotypic and genotypic spectrum. Clin Dysmorphol. 2016 Oct. 25 (4):135-45. [View Abstract]
  6. Spena S, Gervasini C, Milani D. Ultra-Rare Syndromes: The Example of Rubinstein-Taybi Syndrome. J Pediatr Genet. 2015 Sep. 4 (3):177-86. [View Abstract]
  7. Fergelot P, Van Belzen M, Van Gils et al. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations. Am J Med Genet A. 2016 Dec. 170 (12):3069-3082. [View Abstract]
  8. Hamilton MJ, Newbury-Ecob R, Holder-Espinasse M, Yau S, Lillis S, Hurst JA, et al. Rubinstein-Taybi syndrome type 2: report of nine new cases that extend the phenotypic and genotypic spectrum. Clin Dysmorphol. 2016 Oct. 25 (4):135-45. [View Abstract]
  9. López M, García-Oguiza A, Armstrong J, García-Cobaleda I, García-Miñaur S, Santos-Simarro F, et al. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum. BMC Med Genet. 2018 Mar 5. 19 (1):36. [View Abstract]
  10. Tsai AC, Dossett CJ, Walton CS, Cramer AE, Eng PA, Nowakowska BA, et al. Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein-Taybi syndrome detected by aCGH. Eur J Hum Genet. 2011 Jan. 19(1):43-9. [View Abstract]
  11. Blough RI, Petrij F, Dauwerse JG, et al. Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. Am J Med Genet. 2000 Jan 3. 90(1):29-34. [View Abstract]
  12. Roelfsema JH, White SJ, Ariyürek Y, et al. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet. 2005 Apr. 76(4):572-80. [View Abstract]
  13. Cantani A, Gagliesi D. Rubinstein-Taybi syndrome. Review of 732 cases and analysis of the typical traits. Eur Rev Med Pharmacol Sci. 1998 Mar-Apr. 2(2):81-7. [View Abstract]
  14. Kumar S, Suthar R, Panigrahi I, Marwaha RK. Rubinstein-Taybi syndrome: Clinical profile of 11 patients and review of literature. Indian J Hum Genet. 2012 May. 18(2):161-6. [View Abstract]
  15. Boot MV, van Belzen MJ, Overbeek LI, Hijmering N, Mendeville M, Waisfisz Q, et al. Benign and malignant tumors in Rubinstein-Taybi syndrome. Am J Med Genet A. 2018 Mar. 176 (3):597-608. [View Abstract]
  16. Wood VE, Rubinstein J. Duplicated longitudinal bracketed epiphysis "kissing delta phalanx" in Rubinstein-Taybi syndrome. J Pediatr Orthop. 1999 Sep-Oct. 19(5):603-6. [View Abstract]
  17. van Genderen MM, Kinds GF, Riemslag FC, Hennekam RC. Ocular features in Rubinstein-Taybi syndrome: investigation of 24 patients and review of the literature. Br J Ophthalmol. 2000 Oct. 84(10):1177-84. [View Abstract]
  18. Schorry EK, Keddache M, Lanphear N, et al. Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am J Med Genet A. 2008 Oct 1. 146A(19):2512-9. [View Abstract]
  19. Sener RN. Bilateral extra tarsal bones in Rubinstein-Taybi syndrome: the fourth cuneiform bones. Eur Radiol. 1999. 9(3):483-4. [View Abstract]
  20. Siraganian PA, Rubinstein JH, Miller RW. Keloids and neoplasms in the Rubinstein-Taybi syndrome. Med Pediatr Oncol. 1989. 17(6):485-91. [View Abstract]
  21. Bayle P, Bazex J, Lamant L, Lauque D, Durieu C, Albes B. Multiple perforating and non perforating pilomatricomas in a patient with Churg-Strauss syndrome and Rubinstein-Taybi syndrome. J Eur Acad Dermatol Venereol. 2004 Sep. 18(5):607-10. [View Abstract]
  22. Gomez Centeno P, Roson E, Peteiro C, Mercedes Pereiro M, Toribio J. Rubinstein--Taybi syndrome and ulerythema ophryogenes in a 9-year-old boy. Pediatr Dermatol. 1999 Mar-Apr. 16(2):134-6. [View Abstract]
  23. Nakai K, Yoneda K, Moriue T, Kubota Y. Striate palmoplantar keratoderma in a patient with Rubinstein-Taybi syndrome. J Eur Acad Dermatol Venereol. 2008 Jul 9. [View Abstract]
  24. Stevens CA, Bhakta MG. Cardiac abnormalities in the Rubinstein-Taybi syndrome. Am J Med Genet. 1995 Nov 20. 59(3):346-8. [View Abstract]
  25. Verstegen MJ, van den Munckhof P, Troost D, Bouma GJ. Multiple meningiomas in a patient with Rubinstein-Taybi syndrome. Case report. J Neurosurg. 2005 Jan. 102(1):167-8. [View Abstract]
  26. Wiley S, Swayne S, Rubinstein JH, Lanphear NE, Stevens CA. Rubinstein-Taybi syndrome medical guidelines. Am J Med Genet A. 2003 Jun 1. 119A(2):101-10. [View Abstract]

Facial abnormalities (eg, hypoplastic maxilla, prominent beaked nose, antimongoloid palpebral fissures) and broad thumbs in a child with Rubinstein-Taybi syndrome.

Prominent beaked nose, low-set ears, and broad thumbs in a child with Rubinstein-Taybi syndrome.

Broad great toes in a child with Rubinstein-Taybi syndrome.

Facial abnormalities (eg, hypoplastic maxilla, prominent beaked nose, antimongoloid palpebral fissures) and broad thumbs in a child with Rubinstein-Taybi syndrome.

Prominent beaked nose, low-set ears, and broad thumbs in a child with Rubinstein-Taybi syndrome.

Broad great toes in a child with Rubinstein-Taybi syndrome.